Actinogen Medical Limited
ATGGF
$0.03
$0.000.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -40.85% | -41.96% | -- | -- | 129.17% |
| Total Revenue | -40.85% | -41.96% | -- | -- | 129.17% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -40.85% | -41.96% | -- | -- | 129.17% |
| SG&A Expenses | 15.23% | 13.08% | 5.24% | 7.70% | 3.22% |
| Depreciation & Amortization | 4.30% | 2.23% | -4.49% | -2.16% | -1.17% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.20% | 12.06% | -33.45% | -31.89% | 41.87% |
| Operating Income | -324.12% | -316.19% | 28.26% | 26.58% | 54.88% |
| Income Before Tax | -328.85% | -320.81% | 29.32% | 27.67% | 55.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -328.85% | -320.81% | 29.32% | 27.67% | 55.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -328.85% | -320.81% | 29.32% | 27.67% | 55.71% |
| EBIT | -324.12% | -316.19% | 28.26% | 26.58% | 54.88% |
| EBITDA | -360.13% | -351.53% | 28.60% | 26.93% | 57.49% |
| EPS Basic | -250.00% | -250.00% | 50.00% | 50.00% | 66.67% |
| Normalized Basic EPS | -300.00% | -300.00% | 45.45% | 45.45% | 75.00% |
| EPS Diluted | -250.00% | -250.00% | 50.00% | 50.00% | 66.67% |
| Normalized Diluted EPS | -300.00% | -300.00% | 45.45% | 45.45% | 75.00% |
| Average Basic Shares Outstanding | 33.12% | 33.12% | 41.37% | 41.37% | 27.74% |
| Average Diluted Shares Outstanding | 33.12% | 33.12% | 41.37% | 41.37% | 27.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |